Boltz raises $110M Series A led by Bessemer after 50x usage growth
GabriCorso · x · 2026-11-18
AI biomolecular design startup Boltz announced a $110M Series A led by Bessemer Venture Partners. Molecular token usage on its platform has grown 50-fold since June, and the company has signed partnerships with 6 of the world's 20 largest pharma companies, aiming to bring AI-powered biomolecular design to every scientist.
Related event: AI drug design startup Boltz raises $110M Series A as usage surges 50x(10 posts)→
More from Venture
- Perplexity turns Anthropic's S-1 into an interactive 3D-chart explainer — jeffgrimes9 · 2026-11-18
- "Boltz is a biotech exponential" — molecular tokens up 50x since June — GabriCorso · 2026-11-18
- Boltz, the AI lab that moved from MIT to the UK, raises $110M — GabriCorso · 2026-11-18
- 49% of CIOs over token budget: Microsoft made AI cost control the product at Ignite — BenBajarin · 2026-11-18
- Industry figures congratulate Boltz on its $110M Series A — GabriCorso · 2026-11-18
- TSMC now demanding cash upfront to secure capacity as AI demand strains supply chain — ctjlewis · 2026-11-18